World News

Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease...

Ogkologos - 21 Ιουλίου, 2025

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head...

Ogkologos - 18 Ιουλίου, 2025

EMA Recommends Extending Indications for Durvalumab

Ogkologos - 17 Ιουλίου, 2025

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR,...

Ogkologos - 16 Ιουλίου, 2025

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in...

Ogkologos - 16 Ιουλίου, 2025

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell...

Ogkologos - 15 Ιουλίου, 2025

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab...

Ogkologos - 14 Ιουλίου, 2025

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell...

Ogkologos - 11 Ιουλίου, 2025

EMA Recommends Extension of Indications for Cabozantinib

Ogkologos - 10 Ιουλίου, 2025

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation...

Ogkologos - 9 Ιουλίου, 2025

1...444546...432 Σελίδα 45 από 432

MOST POPULAR

Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung...

10 Νοεμβρίου, 2026

Foodie Fridays: It’s Cucumber Season!

23 Ιουλίου, 2021

Safety and Preliminary Signs of Activity of OMO-103, a MYC Inhibitor,...

9 Φεβρουαρίου, 2024

Risk Tool Predicts Severe Chemotherapy Toxicity in Elderly Patients with Early...

21 Ιανουαρίου, 2021

Φόρτωση περισσοτέρων

Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease...

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head...

EMA Recommends Extending Indications for Durvalumab

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR,...

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in...

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell...

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab...

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell...

EMA Recommends Extension of Indications for Cabozantinib

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation...

MOST POPULAR

Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung...

Foodie Fridays: It’s Cucumber Season!

Safety and Preliminary Signs of Activity of OMO-103, a MYC Inhibitor,...

Risk Tool Predicts Severe Chemotherapy Toxicity in Elderly Patients with Early...

HOT NEWS

Facing Crisis After Crisis During Cancer: How to Cope

Woman with Strong Family History of Cancer Finally Gets Diagnosis After...

Simple Hysterectomy May Expand Treatment Options for Early-Stage Cervical Cancer

Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ